Objective To investigate the effect of sindilizumab combined with docetaxel+oxaliplatin+S-1(DOS)regimen on the expression of lysine demethylase 3A(KDM3A)in advanced gastric cancer tissues and its therapeutic mechanism.Methods A total of 104 patients with advanced gastric cancer admitted to our hospital from June 2019 to June 2021 were divided into the control group(n=52)and observation group(n=52).The DOS regimen was applied to both groups,and patients in the observation group were additionally treated with sindilizumab.Tumor markers,including carcinoembryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate sugar antigen 125(CA125);tumor immune molecules before treatment(CD9,CD63,CD168,CD151);positive expressions of programmed death receptor-1(PD-1),PD-L1 and KDM3A;the Karnofsky functional status(KPS)score;adverse effects;survival and prognosis were compared between groups.Results After treatment,CEA,CA724 and CA125 in observation group were significantly lower compared with those of control group(P＜0.05).After treatment,CD168 and CD151 were significantly lower,while CD9 and CD63 were significantly higher in observation group compared with those of control group(P＜0.05).After treatment,the positive rates of PD-1,PD-L1 and KDM3A in the observation group were significantly lower compared with those of control group(P＜0.05).After treatment,KPS score of observation group was significantly higher compared with that of control group(P＜0.05).Compared with those of control group,the objective effective rate and disease control rate of observation group were significantly higher(P＜0.05).There was no significant difference in the incidence adverse events between the two groups(P＞0.05).Compared with those of the control group,the median survival time,12-month and 24-month survival rate of observation group were significantly longer(P＜0.05).Conclusion Sindilizumab combined with DOS regimen can inhibit the secretion of tumor markers in patients with advanced gastric cancer and prolong the lifespan by inhibiting the PD-1/PD-L1 signal transduction,improving body immunity,reducing KDM3A activity,and suppressing tumor cell proliferation and migration.
维普
万方数据
